deferoxamine has been researched along with Kidney Diseases in 26 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 7.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 7.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
| " Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme." | 7.74 | Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. ( Burigo, M; Constantino, L; Dal-Pizzol, F; Di-Pietro, PB; Dias, ML; Machado, RA; Scaini, G; Streck, EL, 2008) |
| "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction." | 3.76 | Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. ( Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V, 2010) |
| "We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 3.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
| " Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme." | 3.74 | Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. ( Burigo, M; Constantino, L; Dal-Pizzol, F; Di-Pietro, PB; Dias, ML; Machado, RA; Scaini, G; Streck, EL, 2008) |
| "Nineteen transfusion-dependent beta-thalassemia major patients were included in the study." | 2.67 | Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. ( Carta, S; Cianciulli, P; Forte, L; Gilardi, E; Massa, A; Papa, G; Sollecito, D; Sorrentino, F, 1994) |
| "Deferoxamine (DFO) is a recognized iron chelator which has been shown to exert nephroprotection in models of toxic nephropathies." | 1.38 | Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation. ( Hernández-Pando, R; Medina-Campos, ON; Molina-Jijón, E; Pedraza-Chaverri, J; Pinzón, E; Tapia, E; Zarco-Márquez, G; Zataraín-Barrón, ZL; Zavaleta, RM, 2012) |
| "We report a case of thalassemia major with biopsy-proven pulmonary iron overload, in which thoracic high-resolution computed tomography revealed a morphological-functional correlation consistent with small airway disease." | 1.31 | Pulmonary iron overload in thalassemia major presenting as small airway disease. ( Khong, PL; Lam, WK; Ooi, GC; Trendell-Smith, NJ; Tsang, KW, 2002) |
| " Previous work has shown that 3,4-dichloroaniline is acutely toxic to the kidney and bladder." | 1.31 | 3,4-Dichlorophenylhydroxylamine cytotoxicity in renal cortical slices from Fischer 344 rats. ( Ball, JG; Rankin, GO; Stoll, S; Valentovic, M, 2001) |
| "Our findings suggest that DFO administration may be safe and useful for ameliorating cisplatin-induced nephrotoxicity." | 1.31 | Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity. ( Dokucu, AI; Ece, A; Ozdemir, E; Oztürk, H; Uzunlar, AK; Yaldiz, M, 2002) |
| " More frequent dosing and/or a longer duration of HP treatment might produce greater reversal of the Al-induced toxicity and perhaps reveal more adverse effects than seen in this study." | 1.30 | Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity. ( Dickey, KM; Fredenburg, AM; Hong, CB; Meurer, KA; Skinner, TL; Yokel, RA, 1997) |
| " When administered to rodents at a daily dosage of 384 mumol/kg over a period of 10 days, drug 1 demonstrated severe renal toxicity." | 1.29 | A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. ( Bergeron, RJ; Creary, EA; Daniels, RD; King, W; Luchetta, G; Moerker, T; Peter, HH; Streiff, RR; Wiegand, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (19.23) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, AC | 1 |
| Zager, RA | 1 |
| Ikeda, Y | 1 |
| Ozono, I | 1 |
| Tajima, S | 1 |
| Imao, M | 1 |
| Horinouchi, Y | 1 |
| Izawa-Ishizawa, Y | 1 |
| Kihira, Y | 1 |
| Miyamoto, L | 1 |
| Ishizawa, K | 1 |
| Tsuchiya, K | 1 |
| Tamaki, T | 1 |
| Dee, CM | 1 |
| Cheuk, DK | 1 |
| Ha, SY | 1 |
| Chiang, AK | 1 |
| Chan, GC | 1 |
| Economou, M | 1 |
| Printza, N | 1 |
| Teli, A | 1 |
| Tzimouli, V | 1 |
| Tsatra, I | 2 |
| Papachristou, F | 2 |
| Athanassiou-Metaxa, M | 1 |
| Barbosa, PR | 1 |
| Cardoso, MR | 1 |
| Daufenbach, JF | 1 |
| Gonçalves, CL | 1 |
| Machado, RA | 2 |
| Roza, CA | 1 |
| Scaini, G | 2 |
| Rezin, GT | 1 |
| Schuck, PF | 1 |
| Dal-Pizzol, F | 2 |
| Streck, EL | 2 |
| Molina-Jijón, E | 1 |
| Zarco-Márquez, G | 1 |
| Medina-Campos, ON | 1 |
| Zataraín-Barrón, ZL | 1 |
| Hernández-Pando, R | 1 |
| Pinzón, E | 1 |
| Zavaleta, RM | 1 |
| Tapia, E | 1 |
| Pedraza-Chaverri, J | 1 |
| Ooi, GC | 1 |
| Khong, PL | 1 |
| Lam, WK | 1 |
| Trendell-Smith, NJ | 1 |
| Tsang, KW | 1 |
| Koliakos, G | 1 |
| Koussi, A | 1 |
| Perifanis, V | 1 |
| Souliou, E | 1 |
| Athanasiou, M | 1 |
| Kadkhodaee, M | 1 |
| Gol, A | 1 |
| Diskin, CJ | 1 |
| Thomas, CE | 1 |
| Mohkam, M | 1 |
| Shamsian, BS | 1 |
| Gharib, A | 1 |
| Nariman, S | 1 |
| Arzanian, MT | 1 |
| Di-Pietro, PB | 1 |
| Dias, ML | 1 |
| Burigo, M | 1 |
| Constantino, L | 1 |
| Cianciulli, P | 1 |
| Sollecito, D | 1 |
| Sorrentino, F | 1 |
| Forte, L | 1 |
| Gilardi, E | 1 |
| Massa, A | 1 |
| Papa, G | 1 |
| Carta, S | 1 |
| Herman, EH | 1 |
| Zhang, J | 1 |
| Ferrans, VJ | 1 |
| Bergeron, RJ | 1 |
| Streiff, RR | 1 |
| Creary, EA | 1 |
| Daniels, RD | 1 |
| King, W | 1 |
| Luchetta, G | 1 |
| Wiegand, J | 1 |
| Moerker, T | 1 |
| Peter, HH | 1 |
| Giardina, PJ | 1 |
| Grady, RW | 1 |
| Yokel, RA | 1 |
| Meurer, KA | 1 |
| Hong, CB | 1 |
| Dickey, KM | 1 |
| Skinner, TL | 1 |
| Fredenburg, AM | 1 |
| Valentovic, M | 1 |
| Ball, JG | 1 |
| Stoll, S | 1 |
| Rankin, GO | 1 |
| Ozdemir, E | 1 |
| Dokucu, AI | 1 |
| Uzunlar, AK | 1 |
| Ece, A | 1 |
| Yaldiz, M | 1 |
| Oztürk, H | 1 |
| Toriyama, T | 1 |
| Kawahara, H | 1 |
| Li Volti, S | 1 |
| Di Gregorio, F | 1 |
| Schilirò, G | 1 |
| Hamed, LM | 1 |
| Winward, KE | 1 |
| Glaser, JS | 1 |
| Schatz, NJ | 1 |
| Althoff, H | 2 |
| Pannacciulli, I | 1 |
| Paravidino, GF | 1 |
| Siccardi, G | 1 |
| Walsh, JR | 1 |
| Brodeur, MT | 1 |
| Ritzmann, LW | 1 |
| Sutherland, DW | 1 |
| Starr, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease[NCT00769834] | 0 participants (Actual) | Observational | 2010-01-31 | Withdrawn (stopped due to All investigators have moved to different oranizations) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Kidney Diseases
| Article | Year |
|---|---|
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
1 trial available for deferoxamine and Kidney Diseases
| Article | Year |
|---|---|
Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy.
Topics: Administration, Cutaneous; Adolescent; Adult; beta 2-Microglobulin; beta-Thalassemia; Child; Child, | 1994 |
24 other studies available for deferoxamine and Kidney Diseases
| Article | Year |
|---|---|
Catalytic iron mediated renal stress responses during experimental cardiorenal syndrome 1 ("CRS-1").
Topics: Animals; Biomarkers; Cardio-Renal Syndrome; Cell Line; Deferoxamine; Gene Expression Regulation; Hea | 2021 |
Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
Topics: Animals; Blotting, Western; Chelation Therapy; Deferoxamine; Fibrosis; Immunohistochemistry; Iron Ch | 2014 |
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; | 2014 |
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; | 2010 |
Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine.
Topics: Acetylcysteine; Animals; Cell Respiration; Deferoxamine; Disease Models, Animal; Drug Combinations; | 2010 |
Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation.
Topics: Animals; Antidotes; Catalase; Chelating Agents; Chromium; Deferoxamine; Glutathione; In Vitro Techni | 2012 |
Pulmonary iron overload in thalassemia major presenting as small airway disease.
Topics: Adult; Airway Obstruction; beta-Thalassemia; Biopsy; Chelation Therapy; Combined Modality Therapy; D | 2002 |
Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Albuminuria; beta 2-Microglobulin; beta-Thalassemia; | 2003 |
The role of nitric oxide in iron-induced rat renal injury.
Topics: Animals; Arginine; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitor | 2004 |
Is it time to reexamine KDOQI aluminum guidelines?
Topics: Aluminum; Deferoxamine; Humans; Kidney Diseases; Practice Guidelines as Topic; Renal Dialysis; Sider | 2006 |
Early markers of renal dysfunction in patients with beta-thalassemia major.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Biomarkers; Blood Glucose; Case-Control Studies; C | 2008 |
Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration.
Topics: Acetylcysteine; Animals; Antioxidants; Brain; Brain Diseases, Metabolic; Creatine Kinase; Deferoxami | 2008 |
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injec | 1994 |
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Topics: Animals; Cebus; Deferoxamine; Dihydropyridines; Feces; Gastrointestinal Diseases; Iron; Kidney Disea | 1993 |
Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
Topics: Administration, Oral; Aluminum Compounds; Anemia; Animals; Bile; Chelating Agents; Deferoxamine; Kid | 1997 |
3,4-Dichlorophenylhydroxylamine cytotoxicity in renal cortical slices from Fischer 344 rats.
Topics: Analysis of Variance; Aniline Compounds; Animals; Ascorbic Acid; Deferoxamine; Dithiothreitol; Dose- | 2001 |
Experimental study on effects of deferoxamine mesilate in ameliorating cisplatin-induced nephrotoxicity.
Topics: Animals; Biopsy, Needle; Cisplatin; Deferoxamine; Disease Models, Animal; Dose-Response Relationship | 2002 |
[Small volume plasma exchange therapy in patients with porphyria cutanea tarda on maintenance hemodialysis].
Topics: Deferoxamine; Erythropoietin; Humans; Kidney Diseases; Male; Middle Aged; Plasma Exchange; Porphyria | 1992 |
Acute changes in renal function associated with deferoxamine therapy.
Topics: Deferoxamine; Humans; Kidney Diseases; Thalassemia | 1990 |
Optic neuropathy in uremia.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Diseases; Male; Methylprednisolone; Middle Aged; Optic N | 1989 |
[Effect of desferrioxamine B on tissue sections of hemosiderosis of the kidney].
Topics: Adrenal Glands; Adult; Blood Transfusion; Buffers; Cortisone; Deferoxamine; Fats; Hemoglobinuria, Pa | 1966 |
[The desferrioxamine test in patients with kidney diseases].
Topics: Acute Kidney Injury; Deferoxamine; Humans; Iron; Kidney Diseases | 1971 |
[Massive renal hemosiderosis in Marchiafava anemia and the possibility of an in-vitro desferrization through desferriofamine B].
Topics: Adult; Deferoxamine; Erythrocyte Count; Hemoglobinuria; Hemosiderosis; Humans; Kidney Diseases; Kidn | 1967 |
Urinary iron excretion in patients with prosthetic heart valves.
Topics: Anemia, Hemolytic; Blood Transfusion; Chromium Isotopes; Deferoxamine; Erythrocytes; Heart Valve Pro | 1966 |